Management
President & Chief Executive OfficerMahesh V. Patel, PH.D.
Mahesh V. Patel, Ph.D. has served as our President and Chief Executive Officer and as a member of our Board of Directors since 1997. Dr. Patel has more than 30 years of experience in strategic planning, technology assessment/development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah. We believe Dr. Patel’s dual role as an executive officer and director gives him unique insights into the day-to-day operations of our company and our strategic planning and clinical development.
Principal Accounting Officer & Corporate ControllerKrista Fogarty
Krista Fogarty, MAcc, has served as our Principal Accounting Officer since January 2022 and our Corporate Controller since October 2018. Ms. Fogarty previously served as Chief Financial Officer at Alternative Behavior Strategies, a provider of ABA therapy services from 2017 to 2018, and as Controller and Associate VP Business Operations at Navigen, a pharmaceutical discovery and drug development company, from 2016 to 2017. Prior to that she served as VP Finance at Lineagen, a personal genomics and biotechnology company from 2013 to 2016. Ms. Fogarty also previously served as Corporate Controller at NPS Pharmaceuticals, a biotechnology company. Ms. Fogarty received a B.S. in Accounting from Utah State University and also received a MAcc from Utah State University
Chief Medical DirectorAnthony Delconte, M.D.
Dr. Anthony DelConte has over 25 years of experience in the healthcare industry. Currently, he is an Assistant Professor of Pharmaceutical and Healthcare Marketing at Saint Joseph’s University and founder of DC Medical Consulting LLC, an advisory and consulting firm focusing on clinical development, medical affairs, and drug safety activities. Previously Dr. DelConte was Chief Medical Officer at Auxilium Pharmaceuticals (NASDAQ: AUXL), and held positions of increasing responsibility at Wyeth, now Pfizer (NYSE: PFE) and Novartis Pharmaceuticals (NYSE: NVS). He also served on the faculty at Jefferson Medical College of Thomas Jefferson University. Dr. DelConte holds a Bachelor of Science in Biology from Saint Joseph’s University and earned his Medical Degree from the University of Pittsburgh. He is a fellow of the American College of Obstetricians and Gynecologists and a Diplomat of the American Board of Obstetrics and Gynecology. He currently serves as President of the Medical Alumni Association at Saint Joseph’s University.
VP Product DevelopmentChidu Chidambaram, PH.D.
Nachiappan Chidambaram, Ph.D. has served as our Senior Vice President, Research and Development since December 2022 and has over 20 years of product development experience in pharma and biotech. Prior to his promotion, Dr. Chidambaram served as our Vice President, Product Development, since July 2014. Prior to being promoted to Vice President, Product Development, Dr. Chidambaram served in various product development leadership roles with the Company including Associate Director, Product Development, from 2007 to 2014. Prior to joining Lipocine in 2007, Dr. Chidambaram served as the Group Leader at Banner Pharmacaps from 2000 to 2007. He received his Ph.D. in Pharmaceutics from the University of Connecticut in 2000.
Clinical TrialistBenjamin Bruno, M.D.
Dr. Benjamin Bruno has been a clinical trialist for the past 8 years, 6 of which have been with Lipocine focused on drug development. He received his BS in biology from the University of Michigan, and Doctor of Pharmacy (PharmD) and PhD in Pharmaceutics from the University of Utah. His areas of expertise include pharmaceutical clinical development including clinical program and trial design, execution, and analysis, as well as regulatory communication and dissemination of study results.
